Ergomed plc, a leading provider of specialised services to the pharmaceutical industry, is headquartered in Great Britain. Founded in 1997, the company has established a strong presence in key operational regions, including Europe and North America. Ergomed focuses on two main business areas: drug development and post-marketing services, offering a unique blend of expertise that enhances the efficiency of clinical trials.
With a commitment to quality and innovation, Ergomed provides a range of core services, including clinical research, pharmacovigilance, and regulatory affairs. The company has achieved notable milestones, such as its successful listing on the London Stock Exchange, solidifying its position as a trusted partner in the life sciences sector. Ergomed's dedication to tailored solutions and client satisfaction sets it apart in a competitive market.
-6 vs industry average
Ergomed’s score of 26 is lower than 47% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Ergomed?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Business Services has below-average carbon intensity
Industry performance
The Business Services industry has increased its overall emissions by 24% since 2019
Emissions trajectory 2020 – 2025
Reported emissions
Scope 3 accounts for ••• of total emissions.
Ergomed's reported carbon emissions
In 2022, Ergomed, headquartered in Great Britain, reported total carbon emissions of approximately 46,150 kg CO2e. This figure includes Scope 1 emissions of 730 kg CO2e, primarily from stationary combustion, Scope 2 emissions of 14,290 kg CO2e from purchased electricity, and significant Scope 3 emissions of 29,980 kg CO2e, which encompass business travel and upstream transportation and distribution. Ergomed has committed to near-term climate targets, although specific reduction targets have not been detailed. The company is actively engaged in sustainability initiatives within the Pharmaceuticals, Biotechnology, and Life Sciences sector. Their emissions data is sourced directly from Ergomed Group Limited, ensuring accuracy and relevance. In comparison, the previous year, 2021, saw total emissions of approximately 60,640 kg CO2e, indicating a reduction in emissions in 2022. Ergomed's ongoing commitment to addressing climate change reflects its dedication to sustainability and responsible corporate practices.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Ergomed’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Ergomed yet.
Scope 3 top emissions categories
2 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Ergomed
Frequently asked questions
Common questions about Ergomed’s sustainability data and climate commitments
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project